RxDoctor Payments Data

Melisa Hockett

Corneal and Contact Management · Orlando, FLNPI 1003122276

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,132 of the $4,237 with a category attached, or 73.9%. 17 manufacturers reported payments, led by Alcon at 28.6% of the total. Reporting peaked in 2024 at $1,558 and has fallen 54.5% since, to $709 in 2025.

$4,237in general payments, 2019–2025

Across 132 payments — averaging $32.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Coopervision Inc.$604
  • Bausch & Lomb Americas Inc.$523
  • AbbVie$357
  • Sun Pharmaceutical Industries Inc.$306
  • Dompe US, Inc.$274
  • plus $960 from 11 others

What the payments were for

  • Speaking & faculty fees$1,00024%
  • Food & beverage$3,13274%
  • Entertainment$1052%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,237 in reported general payments places this provider in the 80th percentile of 67 corneal and contact management providers in Florida.

See all corneal and contact management providers in Florida

Medicare billing

Part B allowed, 2024
$44,573
Medicare patients
264
Services billed
473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj16$907,716
RestasisCyclosporine44$48,301
Cyclosporine66$38,441
XiidraLifitegrast22$20,113
Fluorometholone44$3,552
Latanoprost34$772
Timolol Maleate11$253
ErythromycinErythromycin Base18$192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$274$907,71616 claims
AbbVieRestasis$357$48,30144 claims
Bausch & Lomb Americas Inc.Xiidra$523$20,11322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 67 corneal and contact management providers in Florida.

Other corneal and contact management in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →